Zobrazeno 1 - 10
of 40
pro vyhledávání: '"D F, Bajorin"'
Autor:
J E, Rosenberg, S, Halabi, B L, Sanford, A L, Himelstein, J N, Atkins, R J, Hohl, F, Millard, D F, Bajorin, E J, Small, Nancy, Bartlett
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(5)
There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity again
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97afb215baa3f01e4b01ca89e6a43c35
https://pubmed.ncbi.nlm.nih.gov/18272914
https://pubmed.ncbi.nlm.nih.gov/18272914
Autor:
D F, Bajorin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e86793885263fc76e0435f41d91999fa
https://pubmed.ncbi.nlm.nih.gov/11560966
https://pubmed.ncbi.nlm.nih.gov/11560966
Autor:
F C, Maluf, D F, Bajorin
Publikováno v:
Seminars in urologic oncology. 19(1)
Transitional cell carcinoma is a malignancy in which a number of single agents with different mechanisms of action are effective. Most older agents have limited activity, but several combinations are quite active. The most common regimens over the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f09c8fb3f7464e4ccb673f4b1cc91ba1
https://pubmed.ncbi.nlm.nih.gov/11246730
https://pubmed.ncbi.nlm.nih.gov/11246730
Publikováno v:
The Journal of urology. 165(3)
We update our experience with post-chemotherapy surgery in patients with unresectable or lymph node positive bladder cancer.Of 207 patients with unresectable or regionally metastatic bladder cancer 80 (39%) underwent post-chemotherapy surgery after t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80cd5e9d665fb669551a17714befd333
https://pubmed.ncbi.nlm.nih.gov/11176475
https://pubmed.ncbi.nlm.nih.gov/11176475
Autor:
D F, Bajorin, J A, McCaffrey, P M, Dodd, S, Hilton, M, Mazumdar, W K, Kelly, H, Herr, H I, Scher, E, Icasiano, G, Higgins
Publikováno v:
Cancer. 88(7)
A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dbdda4b36ff24f837a7ff394a7cbe5da
https://pubmed.ncbi.nlm.nih.gov/10738226
https://pubmed.ncbi.nlm.nih.gov/10738226
Autor:
D F, Bajorin
Publikováno v:
Oncology (Williston Park, N.Y.). 14(1)
Median survival in patients with advanced urothelial carcinoma continues to be approximately 1 year following treatment with traditional cisplatin (Platinol)-based regimens, which have substantial toxicity. Thus, research is focusing on newer chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::690680e76cb5517dbf3e0f1d00648fc8
https://pubmed.ncbi.nlm.nih.gov/10680149
https://pubmed.ncbi.nlm.nih.gov/10680149
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(9)
More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2fbac177beee2edc515a33b764838264
https://pubmed.ncbi.nlm.nih.gov/10499642
https://pubmed.ncbi.nlm.nih.gov/10499642
Autor:
P M, Dodd, J A, McCaffrey, M, Mazumdar, H, Scher, V, Vlamis, G, Higgins, H, Herr, D F, Bajorin
Publikováno v:
Cancer. 85(5)
This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d12ea29412067c2e4e65f72b23dec79
https://pubmed.ncbi.nlm.nih.gov/10091800
https://pubmed.ncbi.nlm.nih.gov/10091800
Publikováno v:
The Journal of urology. 161(1)
We evaluated whether the p53 status of invasive bladder cancer may help to select patients for treatment strategies aimed at bladder preservation.A total of 111 patients with muscle invasive (T2 to 3N0M0) transitional cell carcinoma of the bladder re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ebe2d6f9bc6fc7bb308ab427076046b0
https://pubmed.ncbi.nlm.nih.gov/10037370
https://pubmed.ncbi.nlm.nih.gov/10037370
Publikováno v:
The Urologic clinics of North America. 25(3)
Standard therapy for patients with poor-risk germ cell tumors remains four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, which cures approximately 50% of this patient population. Randomized trials of conventional-dose chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::818a1c920c9eaa8328956f7b28050ec8
https://pubmed.ncbi.nlm.nih.gov/9728218
https://pubmed.ncbi.nlm.nih.gov/9728218